| 1. |
- Aad, G., et al.
(author)
-
- 2014
-
In: Journal of High Energy Physics. - 1029-8479 .- 1126-6708. ; :6
-
Journal article (peer-reviewed)
|
|
| 2. |
- Aad, G., et al.
(author)
-
- 2012
-
swepub:Mat__t (peer-reviewed)
|
|
| 3. |
- Aad, G., et al.
(author)
-
- 2014
-
In: Journal of High Energy Physics. - 1029-8479 .- 1126-6708. ; :6
-
Journal article (peer-reviewed)
|
|
| 4. |
- Aad, G., et al.
(author)
-
- 2013
-
In: Journal of High Energy Physics. - 1029-8479 .- 1126-6708. ; :11
-
Journal article (peer-reviewed)
|
|
| 5. |
- Aad, G., et al.
(author)
-
- 2011
-
swepub:Mat__t (peer-reviewed)
|
|
| 6. |
- Ruhal, Rohit, et al.
(author)
-
Trends in bacterial trehalose metabolism and significant nodes of metabolic pathway in the direction of trehalose accumulation
- 2013
-
In: Microbial Biotechnology. - : Wiley. - 1751-7907 .- 1751-7915. ; 6:5, s. 493-502
-
Journal article (peer-reviewed)abstract
- The current knowledge of trehalose biosynthesis under stress conditions is incomplete and needs further research. Since trehalose finds industrial and pharmaceutical applications, enhanced accumulation of trehalose in bacteria seems advantageous for commercial production. Moreover, physiological role of trehalose is a key to generate stress resistant bacteria by metabolic engineering. Although trehalose biosynthesis requires few metabolites and enzyme reactions, it appears to have a more complex metabolic regulation. Trehalose biosynthesis in bacteria is known through three pathways - OtsAB, TreYZ and TreS. The interconnections of in vivo synthesis of trehalose, glycogen or maltose were most interesting to investigate in recent years. Further, enzymes at different nodes (glucose-6-P, glucose-1-P and NDP-glucose) of metabolic pathways influence enhancement of trehalose accumulation. Most of the study of trehalose biosynthesis was explored in medically significant Mycobacterium, research model Escherichia coli, industrially applicable Corynebacterium and food and probiotic interest Propionibacterium freudenreichii. Therefore, the present review dealt with the trehalose metabolism in these bacteria. In addition, an effort was made to recognize how enzymes at different nodes of metabolic pathway can influence trehalose accumulation.
|
|
| 7. |
- Aad, G., et al.
(author)
-
- 2012
-
In: Journal of High Energy Physics. - 1029-8479 .- 1126-6708. ; :12
-
Journal article (peer-reviewed)
|
|
| 8. |
- Aad, G., et al.
(author)
-
- 2015
-
In: Journal of High Energy Physics. - 1029-8479 .- 1126-6708. ; :1
-
Journal article (peer-reviewed)
|
|
| 9. |
- Suneson, Klara, et al.
(author)
-
Omega-3 fatty acids for inflamed depression - A match/mismatch study
- 2024
-
In: Brain, Behavior, and Immunity. - 1090-2139. ; 118, s. 192-201
-
Journal article (peer-reviewed)abstract
- Despite decades of research on the pathophysiology of depression, the development of new therapeutic interventions has been slow, and no biomarkers of treatment response have been clinically implemented. Several lines of evidence suggest that the clinical and biological heterogeneity among patients with major depressive disorder (MDD) has hampered progress in this field. MDD with low-grade inflammation - "inflamed depression" - is a subtype of depression that may be associated with a superior antidepressant treatment response to anti-inflammatory compounds. Omega-3 fatty acid eicosapentaenoic acid (EPA) has anti-inflammatory properties, and preliminary data suggest that it may be particularly efficacious in inflamed depression. In this study we tested the hypothesis that add-on EPA has greater antidepressant efficacy in MDD patients with high baseline high-sensitivity C-reactive protein (hs-CRP) compared to MDD patients with low hs-CRP. All subjects received 2.2 g EPA, 400 mg docosahexaenoic acid and 800 mg of other fatty acids daily for 8 weeks, added to stable ongoing antidepressant treatment. The primary outcome was change in the 17-item Hamilton Depression Rating Scale (HAMD-17). Patients and raters were blind to baseline hs-CRP status. In an intention-to-treat analysis including all subjects with at least one post baseline visit (n = 101), ahs-CRPcut-off of ≥1 mg/L, but not ≥3 mg/L, was associated with a greater improvement in HAMD-17 total score. In addition to a general antidepressant effect among patients with hs-CRP ≥ 1 mg/L, adjuvant EPA treatment improved symptoms putatively related to inflamed depression such as fatigue and sleep difficulties. This adds to the mounting evidence that delineation of MDD subgroups based on inflammation may be clinically relevant to predict treatment response to anti-inflammatory interventions.
|
|
| 10. |
|
|
